Key clinical point: A chemotherapy-free regimen has produced promising early response and survival outcomes in patients with a particularly poor-prognosis subtype of diffuse large B-cell lymphoma (DLBCL).
Major finding: The overall response rate was 86% after two cycles of combined rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed non–germinal center (non-GCB) DLBCL.
Study details: Smart Start, an investigator-initiated phase 2 study enrolling 60 patients with non-GCB DLBCL.
Disclosures: The study received research support and funding from the ASCO Conquer Cancer Foundation. The trial drug and support were provided by Celgene and Janssen. Dr. Westin reported disclosures related to Celgene, Genentech/Abbvie, Kite Pharma, Kite/Gilead, Novartis, ProNAi, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Janssen, and Karyopharm Therapeutics.
Westin J et al. ASCO 2019, Abstract 7508.